COMMUNIQUÉS West-GlobeNewswire

ORYZON Raises €30 Million in Capital Increase
24/04/2025
Issued 12,765,958 new shares Priced at €2.35 per share, representing a 15.44% discount on the 5-day VWAP Strong investor demand, with the offering significantly oversubscribed €15 million anchored by a leading US [...]
ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100’s Development Status
24/04/2025
WESTON, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with [...]
Tonix Pharmaceuticals Presented Data on Potential Mpox Vaccine TNX-801 at World Vaccine Congress Washington 2025
24/04/2025
TNX-801 is a single-dose, live virus vaccine in development to protect against mpox and smallpox TNX-801 protects immunocompromised animals from a lethal challenge with clade IIa monkeypox virus Durability of TNX-801 [...]
Nerve Renew Under Review & Ingredients Guide | Best Nerve Pain Supplement Explained
24/04/2025
Nerve Renew is a dietary supplement formulated to support nerve health, particularly for individuals experiencing symptoms of peripheral neuropathy such as tingling, numbness, burning sensations, or nerve pain Eagle, [...]
RadNet, Inc. Announces Date of its First Quarter 2025 Financial Results Conference Call
24/04/2025
LOS ANGELES, April 24, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) , a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient [...]
ITM and Alpha-9 Oncology Enter Into Supply Agreement for Therapeutic Medical Radioisotope Actinium-225
24/04/2025
Garching / Munich, Germany and VANCOUVER, British Columbia, April 24, 2025 – ITM Isotope Technologies Munich SE (ITM) , a leading radiopharmaceutical biotech company, and Alpha-9 Oncology (Alpha-9) , a clinical-stage [...]
Composition of the Nomination Committee of Orion Corporation
24/04/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 24 APRIL 2025 at 11.00 EEST Composition of the Nomination Committee of Orion Corporation The Board of [...]
New survey shows that over 90% of animal owners trust and appreciate veterinary teams but underestimate the demands of the profession
24/04/2025
New survey data show 94% of animal owners appreciate the work of veterinarians 1 , compared to only 49% of veterinary professionals feeling their profession is appreciated, among other findings. 2 The survey confirms [...]
iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial
24/04/2025
For immediate release iSTAR Medical’s MINIject ® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Five-year safety profile including corneal health confirmed and 38% IOP [...]
Actimed Therapeutics Appoints Shaun Claydon as Chief Financial Officer
24/04/2025
London, UK – 24 th April 2025. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
Bioxodes announces positive Phase 2a interim data for BIOX-101 in intracerebral hemorrhagic stroke patients
24/04/2025
Primary endpoint met, no drug-related serious adverse events Positive hematoma and edema volume evolution Recruitment stopped early due to positive exploratory and efficacy outcomes Preparations underway to initiate [...]
Bioxodes annonce des données intermédiaires positives pour son essai de phase 2a portant sur BIOX-101 dans le traitement de l’AVC hémorragique
24/04/2025
Le critère d’évaluation principal a été atteint, aucun événement indésirable grave associé au médicament n’a été rapporté L’évolution du volume de l’hématome et de l’œdème est favorable Le recrutement des patients a été [...]
Late-breaking elafibranor primary sclerosing cholangitis (PSC) data demonstrates favorable safety profile and significant efficacy in second potential rare liver disease indication
24/04/2025
Elafibranor showed a favorable safety profile and demonstrated dose-dependent efficacy over 12 weeks for people living with PSC, a rare liver disease that currently has no approved treatment options Patients treated [...]
Les dernières données sur l’élafibranor démontrent un profil de tolérance favorable et une efficacité significative dans la CSP, une deuxième indication dans les maladies rares du foie
24/04/2025
L’élafibranor a montré un profil de tolérance favorable et a démontré une efficacité en termes de relation dose-effet sur 12 semaines chez des patients atteints de CSP, une maladie rare du foie pour laquelle il n’existe [...]
Pharming Group to report first quarter 2025 financial results on May 8
24/04/2025
Leiden, the Netherlands, April 24, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms it will report its preliminary (unaudited) first quarter 2025 financial results, for the period [...]
ONWARD Medical Establishes US ADR Program and Begins Trading on OTCQX Best Market
24/04/2025
Sponsored Level 1 ADR program facilitates trading by US investors following recent FDA clearance and commercial launch BNY will be ADR depositary bank Ticker symbol for US investors is ONWRY EINDHOVEN, the Netherlands, [...]
Press Release: Sanofi: strong Q1 performance and 2025 guidance confirmed
24/04/2025
Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER 1 and business EPS 2 of €1.79 Pharma launches reached sales of €0.8 billion, up 43.8%, driven by ALTUVIIIO [...]
Communiqué de presse : Sanofi : forte performance au T1 et confirmation des perspectives pour 2025
24/04/2025
Sanofi : forte performance au T1 et confirmation des perspectives pour 2025 Paris, le 24 avril 2025 Ventes du T1 en progression de 9,7 % à TCC 1 et BNPA 2 des activités de 1,79 euro Les ventes des nouveaux lancements [...]
Strong sales for Cresemba® (isavuconazole) in Japan trigger second milestone payment from Asahi Kasei Pharma to Basilea
24/04/2025
Allschwil, Switzerland, April 24, 2025 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal [...]

Pages